Abstract
Eli Lilly and Company will pay $100 million for access to Precision BioSciences’ gene-editing platform. The partners will work together to develop treatments for Duchenne muscular dystrophy and oth...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
